These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

531 related items for PubMed ID: 25832470

  • 1. Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study.
    Buysman EK, Liu F, Hammer M, Langer J.
    Adv Ther; 2015 Apr; 32(4):341-55. PubMed ID: 25832470
    [Abstract] [Full Text] [Related]

  • 2. Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States.
    Mody R, Huang Q, Yu M, Zhao R, Patel H, Grabner M, Landó LF.
    Diabetes Obes Metab; 2019 Apr; 21(4):920-929. PubMed ID: 30520248
    [Abstract] [Full Text] [Related]

  • 3. Predictors of glycemic control and diabetes-related costs among type 2 diabetes patients initiating therapy with liraglutide in the United States.
    Durden E, Lenhart G, Lopez-Gonzalez L, Hammer M, Langer J.
    J Med Econ; 2016 Apr; 19(4):403-13. PubMed ID: 26653068
    [Abstract] [Full Text] [Related]

  • 4. Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation.
    Yu M, Xie J, Fernandez Lando L, Kabul S, Swindle RW.
    Clin Ther; 2016 Jan 01; 38(1):149-60. PubMed ID: 26706658
    [Abstract] [Full Text] [Related]

  • 5. Persistence with Basal-Bolus Insulin Therapy in Patients with Type 2 Diabetes Mellitus and Effect on Clinical and Economic Outcomes: A Retrospective Claims Database Study.
    Edelman SV, Ermakova A, Xiong Y, Sieradzan R, Taylor SD.
    J Manag Care Spec Pharm; 2019 Dec 01; 25(12):1420-1431. PubMed ID: 31550190
    [Abstract] [Full Text] [Related]

  • 6. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
    Pelletier EM, Pawaskar M, Smith PJ, Best JH, Chapman RH.
    J Med Econ; 2012 Dec 01; 15(6):1039-50. PubMed ID: 22533526
    [Abstract] [Full Text] [Related]

  • 7. Real-world cost-effectiveness: lower cost of treating patients to glycemic goal with liraglutide versus exenatide.
    DeKoven M, Lee WC, Bouchard J, Massoudi M, Langer J.
    Adv Ther; 2014 Feb 01; 31(2):202-16. PubMed ID: 24477354
    [Abstract] [Full Text] [Related]

  • 8. The Effect of Early Response to GLP-1 RA Therapy on Long-Term Adherence and Persistence Among Type 2 Diabetes Patients in the United States.
    Durden E, Liang M, Fowler R, Panton UH, Mocevic E.
    J Manag Care Spec Pharm; 2019 Jun 01; 25(6):669-680. PubMed ID: 30896359
    [Abstract] [Full Text] [Related]

  • 9. Retrospective Study on the Impact of Adherence in Achieving Glycemic Goals in Type 2 Diabetes Mellitus Patients Receiving Canagliflozin.
    Buysman EK, Anderson A, Bacchus S, Ingham M.
    Adv Ther; 2017 Apr 01; 34(4):937-953. PubMed ID: 28251556
    [Abstract] [Full Text] [Related]

  • 10. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States.
    Johnston SS, Nguyen H, Felber E, Cappell K, Nelson JK, Chu BC, Kalsekar I.
    Adv Ther; 2014 Nov 01; 31(11):1119-33. PubMed ID: 25408484
    [Abstract] [Full Text] [Related]

  • 11. Effect of V-Go Versus Multiple Daily Injections on Glycemic Control, Insulin Use, and Diabetes Medication Costs Among Individuals with Type 2 Diabetes Mellitus.
    Raval AD, Nguyen MH, Zhou S, Grabner M, Barron J, Quimbo R.
    J Manag Care Spec Pharm; 2019 Oct 01; 25(10):1111-1123. PubMed ID: 31556817
    [Abstract] [Full Text] [Related]

  • 12. A Retrospective Database Study Comparing Diabetes-Related Medication Adherence and Health Outcomes for Mail-Order Versus Community Pharmacy.
    Schwab P, Racsa P, Rascati K, Mourer M, Meah Y, Worley K.
    J Manag Care Spec Pharm; 2019 Mar 01; 25(3):332-340. PubMed ID: 30816817
    [Abstract] [Full Text] [Related]

  • 13. Impact of adherence to antidepressants on healthcare outcomes and costs among patients with type 2 diabetes and comorbid major depressive disorder.
    Vega C, Becker RV, Mucha L, Lorenz BH, Eaddy MT, Ogbonnaya AO.
    Curr Med Res Opin; 2017 Oct 01; 33(10):1879-1889. PubMed ID: 28644095
    [Abstract] [Full Text] [Related]

  • 14. The INITIATOR study: pilot data on real-world clinical and economic outcomes in US patients with type 2 diabetes initiating injectable therapy.
    Thayer S, Wei W, Buysman E, Brekke L, Crown W, Grabner M, Raparla S, Quimbo R, Cziraky MJ, Hu W, Cuddihy R.
    Adv Ther; 2013 Dec 01; 30(12):1128-40. PubMed ID: 24293131
    [Abstract] [Full Text] [Related]

  • 15. Clinical and economic outcomes among patients with diabetes mellitus initiating insulin glargine pen versus vial.
    Grabner M, Chu J, Raparla S, Quimbo R, Zhou S, Conoshenti J.
    Postgrad Med; 2013 May 01; 125(3):204-13. PubMed ID: 23748521
    [Abstract] [Full Text] [Related]

  • 16. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
    Xie L, Zhou S, Pinsky BW, Buysman EK, Baser O.
    Diabetes Technol Ther; 2014 Sep 01; 16(9):567-75. PubMed ID: 24735083
    [Abstract] [Full Text] [Related]

  • 17. Predictors of Change in Adherence Status from 1 Year to the Next Among Patients with Type 2 Diabetes Mellitus on Oral Antidiabetes Drugs.
    Saundankar V, Peng X, Fu H, Ascher-Svanum H, Rodriguez A, Ali A, Slabaugh L, Young P, Louder A.
    J Manag Care Spec Pharm; 2016 May 01; 22(5):467-82. PubMed ID: 27123910
    [Abstract] [Full Text] [Related]

  • 18. Impact of Out-of-Pocket Pharmacy Costs on Branded Medication Adherence Among Patients with Type 2 Diabetes.
    Bibeau WS, Fu H, Taylor AD, Kwan AY.
    J Manag Care Spec Pharm; 2016 Nov 01; 22(11):1338-1347. PubMed ID: 27783549
    [Abstract] [Full Text] [Related]

  • 19. The Association Between Adherence to Insulin Therapy and Health Care Costs for Adults with Type 2 Diabetes: Evidence from a U.S. Retrospective Claims Database.
    Eby EL, Bajpai S, Faries DE, Haynes VS, Lage MJ.
    J Manag Care Spec Pharm; 2020 Sep 01; 26(9):1081-1089. PubMed ID: 32857656
    [Abstract] [Full Text] [Related]

  • 20. Evaluating the relationship between quality measure adherence definitions and economic outcomes in commercial health plans: a retrospective diabetes cohort study.
    Chinthammit C, Axon DR, Mollon L, Taylor AM, Pickering M, Black H, Warholak T, Campbell PJ.
    J Manag Care Spec Pharm; 2021 Jan 01; 27(1):64-72. PubMed ID: 33377445
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.